Atopic dermatitis, psoriasis, and hidradenitis suppurativa (HS) can present differently in diverse patients, potentially leading to delayed diagnosis and therefore delayed treatment, explained James Song, MD, director of clinical research and associate chief medical officer at Frontier Dermatology.
James Song, MD, director of clinical research and associate chief medical officer at Frontier Dermatology, highlights key insights from his 2023 Fall Clinical Dermatology Conference session about recognizing how atopic dermatitis, psoriasis, and hidradenitis suppurativa (HS) affect people differently based on severity and skin tone.
Song co-presented the session with Andrew Alexis, MD, MPH, Andrew Alexis, MD, MPH, FAAD, vice chair for diversity and inclusion for the Department of Dermatology and a dermatologist at the Center for Diverse Skin Complexions at Weill Cornell Medicine in New York City; and Linda Stein Gold, MD, director of Dermatology Clinical Research at Henry Ford Health System.
He explained that there are different presentations of skin diseases in patients who have darker skin, and not having a clear understanding of these differences can result in both a delay in diagnosis and a delay in treatment start.
In addition, patient with skin of color often present with more advanced disease. In a disease like psoriasis, this may not be a problem because there are so many therapies available that can effectively treat the disease. However, with HS, medications don't work as well once the patient has advanced enough to develop tunnels or scarring.
According to Song, patients with skin of color have to get to a dermatologist earlier when there is a better window of opportunity to intervene for the best response to treatment.
In addition to HS being more common in Black and Latinx patients, there is also a disproportionately higher number of patients with skin of color who have severe disease, which is tied to their social determinants of health, he said. They may not have access to specialists or newer medications. They may have lower health literacy. Or due to historical injustices by the medical system, they may simply not trust the system anymore.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More